BETHESDA, Md., June 6, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, today announced that its Chief Technical Officer, Dr. Marnix Bosch , will make a presentation at the Brain Tumor Biotech Summit sponsored by the Weill Cornell Medical College and Voices Against Brain Cancer in New York City, New York on Friday, June 7, 2013.
Dr. Bosch will review NW Bio's non-toxic personalized immune therapies for both operable and inoperable brain tumors, and the clinical trial programs for each of these.
This will include the ongoing 312-patient Phase III international trial of DCVax-L for Glioblastoma multiforme brain cancer, which is currently enrolling patients in both the US and Europe.
It will also include review of the Phase I/II trial of DCVax-Direct, which is expected to be launching soon for all inoperable solid tumors, including tumors that have metastasized to the brain from other locations.
Dr. Bosch will be presenting at the Weill Cornell Medical College's Uris Auditorium at 8:20 am on Friday, June 7, 2013. The Auditorium is located at 1300 New York Avenue at 69th Street. Dr. Bosch's presentation will be available on the NW Bio Website starting at 10:00 am on Friday morning June 7, 2013.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind asso
|SOURCE Northwest Biotherapeutics|
Copyright©2012 PR Newswire.
All rights reserved